Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex as adjunctive therapy for uncontrolled cancer pain on optimized opioids
2009-016064-36Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain and chronic pain comparing Sativex arm with Placebo arm (2 arms). Primary endpoint: Percent improvement in NRS average pain score. Started Jan 2010; status: completed.
02
Drugs
cannabidiol
03
Conditions
cancer painchronic pain
Beyond the preview
Go deeper on 2009-016064-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016064-36.